Open AccessDevelopment of an Insulin Pen is a Patient-Centric Multidisciplinary Undertaking: A Commentary
Author(s) -
Thomas Sparre,
Niels-Aage B Hansen,
Anya Sonia Wernersson,
Mark Guarraia
Publication year - 2021
Publication title -
journal of diabetes science and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.039
H-Index - 75
eISSN - 1932-3107
pISSN - 1932-2968
DOI - 10.1177/19322968211058707
Subject(s) - multidisciplinary approach , medicine , multidisciplinary team , new product development , intensive care medicine , nursing , business , social science , sociology , marketing
The goal of human-centered insulin pen design is to relieve the treatment burden of a chronic condition and help affected individuals to feel free of disease. The patient as well as their entire ecosystem should be considered. At Novo Nordisk A/S, we believe that embedding human-centered design at the heart of our development processes is best achieved with multidisciplinary experts in-house to work alongside product development teams and, importantly, the end user. Novo Nordisk introduced the first commercially available insulin pen in 1985 and has continued to develop reusable/durable and prefilled insulin pens to meet different patient needs, through to the latest NovoPen 6 and NovoPen Echo Plus with SMART technology. Human-centered design is essential for delivering meaningful and practical solutions for individuals with diabetes.